JP2014510265A5 - - Google Patents

Download PDF

Info

Publication number
JP2014510265A5
JP2014510265A5 JP2013552644A JP2013552644A JP2014510265A5 JP 2014510265 A5 JP2014510265 A5 JP 2014510265A5 JP 2013552644 A JP2013552644 A JP 2013552644A JP 2013552644 A JP2013552644 A JP 2013552644A JP 2014510265 A5 JP2014510265 A5 JP 2014510265A5
Authority
JP
Japan
Prior art keywords
cancer
tumor
igfbp
cell
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013552644A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014510265A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/023691 external-priority patent/WO2012106556A2/en
Publication of JP2014510265A publication Critical patent/JP2014510265A/ja
Publication of JP2014510265A5 publication Critical patent/JP2014510265A5/ja
Pending legal-status Critical Current

Links

JP2013552644A 2011-02-02 2012-02-02 Ｉｇｆ−１ｒの阻害に関する方法および組成物 Pending JP2014510265A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161438918P 2011-02-02 2011-02-02
US61/438,918 2011-02-02
PCT/US2012/023691 WO2012106556A2 (en) 2011-02-02 2012-02-02 Methods and compositons relating to inhibition of igf-1r

Publications (2)

Publication Number Publication Date
JP2014510265A JP2014510265A (ja) 2014-04-24
JP2014510265A5 true JP2014510265A5 (enExample) 2015-03-19

Family

ID=45592826

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013552644A Pending JP2014510265A (ja) 2011-02-02 2012-02-02 Ｉｇｆ−１ｒの阻害に関する方法および組成物

Country Status (7)

Country Link
US (1) US20140037642A1 (enExample)
EP (1) EP2671082B1 (enExample)
JP (1) JP2014510265A (enExample)
AU (2) AU2012212075A1 (enExample)
CA (1) CA2825894C (enExample)
MX (1) MX2013008833A (enExample)
WO (1) WO2012106556A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11972450B2 (en) 2005-07-14 2024-04-30 Charles D. Huston Spectator and participant system and method for displaying different views of an event
US8933967B2 (en) 2005-07-14 2015-01-13 Charles D. Huston System and method for creating and sharing an event using a social network
US8207843B2 (en) 2005-07-14 2012-06-26 Huston Charles D GPS-based location and messaging system and method
ES2707551T3 (es) * 2007-03-02 2019-04-04 Amgen Inc Métodos y composiciones para tratar enfermedades tumorales
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
US8961970B2 (en) * 2012-03-20 2015-02-24 Novartis Ag Combination therapy
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
US10799473B2 (en) 2013-03-04 2020-10-13 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of inhibiting IGF-1R activation or downtream signalling thereof to reduce radiation-induced cellular senescence
US10736900B2 (en) * 2014-03-26 2020-08-11 Astex Therapeutics Ltd Combinations of an FGFR inhibitor and an IGF1R inhibitor
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
BR112016022056B1 (pt) 2014-03-26 2023-04-11 Astex Therapeutics Limited Combinação, composição farmacêutica, uso de uma combinação ou uma composição farmacêutica, e, produto farmacêutico
TWI719960B (zh) 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
WO2016182988A1 (en) 2015-05-08 2016-11-17 Memorial Sloan Kettering Cancer Center Compositions and methods for treatment of glioma
HUE050567T2 (hu) 2015-09-23 2020-12-28 Janssen Pharmaceutica Nv Triciklusos heterociklusok rák kezelésére
WO2017050865A1 (en) 2015-09-23 2017-03-30 Janssen Pharmaceutica Nv Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
MX391162B (es) 2015-10-30 2025-03-21 Galaxy Biotech Llc Anticuerpos altamente potentes que se unen a receptor de muerte 4 y receptor de muerte 5
EP3361548B1 (en) 2016-03-30 2020-07-29 LG Chem, Ltd. Lithium secondary battery production method
TW202246339A (zh) * 2021-03-03 2022-12-01 愛爾蘭商赫萊森治療愛爾蘭公司 治療甲狀腺眼疾的方法
WO2023276869A1 (ja) * 2021-06-28 2023-01-05 学校法人 久留米大学 血管新生阻害薬による治療後の予後予測方法および癌の併用療法
EP4403186A4 (en) * 2021-09-16 2026-02-11 Univ Keio PRODUCTION OF AN ORGANOID DERIVED FROM CTC IN A PATIENT WITH SMALL CELL LUNG CANCER, AND AN IGF1R INHIBITOR AS A MOLECULAR-TARGETED DRUG FOR SMALL CELL LUNG CANCER
US20240358739A1 (en) * 2021-09-24 2024-10-31 The Trustees Of Indiana University Composition and method to treat cachexia
CN115089589A (zh) * 2022-06-10 2022-09-23 杭州市肿瘤医院 激酶抑制剂gsk1838705a在制备抑制食管癌的药物中的应用
WO2025155894A1 (en) * 2024-01-19 2025-07-24 Sling Therapeutics, Inc. Use of inhibitors of insulin-like growth factor receptor-1 for fibrotic diseases

Family Cites Families (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
WO1990014363A1 (en) 1989-05-19 1990-11-29 Amgen Inc. Metalloproteinase inhibitor
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
EP0639981A4 (en) 1992-05-08 1995-06-28 Univ Jefferson ANALOGS OF THE IGF FACTOR (01/18/94).
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
FR2714383B1 (fr) 1993-12-29 1996-02-09 Centre Nat Rech Scient Contrôle de l'expression de gènes.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
CA2218503C (en) 1995-04-20 2001-07-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
US6084085A (en) 1995-11-14 2000-07-04 Thomas Jefferson University Inducing resistance to tumor growth with soluble IGF-1 receptor
DK0780386T3 (da) 1995-12-20 2003-02-03 Hoffmann La Roche Matrixmetalloproteaseinhibitorer
EP0923585B1 (en) 1996-07-18 2002-05-08 Pfizer Inc. Phosphinate based inhibitors of matrix metalloproteases
EP0922030A1 (en) 1996-08-23 1999-06-16 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
US6077864A (en) 1997-01-06 2000-06-20 Pfizer Inc. Cyclic sulfone derivatives
US6482795B1 (en) 1997-01-30 2002-11-19 Myriad Genetics, Inc. Tumor suppressor designated TS10q23.3
HUP0000852A2 (hu) 1997-02-03 2001-05-28 Pfizer Products Inc. Aril-szulfonil-amino-hidroxámsav-származékok, valamint e vegyületeket tartalmazó gyógyászati készítmények
JP2000507975A (ja) 1997-02-07 2000-06-27 ファイザー・インク Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
NZ336836A (en) 1997-02-11 2001-02-23 Pfizer Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments
US6051593A (en) 1997-06-20 2000-04-18 Sugen, Inc. 3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors
US6133305A (en) 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US7020563B1 (en) 1997-11-27 2006-03-28 Commonwealth Scientific And Industrial Research Organisation Method of designing agonists and antagonists to IGF receptor
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
WO1999044062A1 (en) * 1998-02-25 1999-09-02 The United States Of America As Represented By The Secretary Department Of Health And Human Services Cellular arrays for rapid molecular profiling
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
AU4079999A (en) 1998-05-15 1999-12-06 Imclone Systems Incorporated Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
JP2002522063A (ja) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド 増加した血清半減期を有する改変された分子の生成
US7173005B2 (en) 1998-09-02 2007-02-06 Antyra Inc. Insulin and IGF-1 receptor agonists and antagonists
US20030236190A1 (en) 1998-09-02 2003-12-25 Renuka Pillutla Isulin and IGF-1 receptor agonists and antagonists
US6875741B2 (en) 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
EP1006184A1 (en) 1998-12-03 2000-06-07 F. Hoffmann-La Roche Ag IGF-1 receptor interacting proteins (IIPs) genes coding therefor and uses thereof
US6608108B2 (en) 1999-10-15 2003-08-19 Johns Hopkins University Method for treatment of tumors using nordihydroguaiaretic acid derivatives
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
US20030165502A1 (en) 2000-06-13 2003-09-04 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
NZ527302A (en) 2001-01-05 2006-10-27 Abgenix Inc Antibodies to insulin-like growth factor I receptor
CA2439559A1 (en) * 2001-02-07 2002-09-06 Baylor College Of Medicine Method to determine prognosis after therapy for prostate cancer
CA2439735A1 (en) 2001-03-14 2002-09-19 Genentech, Inc. Igf antagonist peptides
AU2002334355A1 (en) 2001-09-06 2003-03-18 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
ES2283759T3 (es) 2002-01-18 2007-11-01 Pierre Fabre Medicament Anticuerpos anti-igf-ir y sus aplicaciones.
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
EP1432724A4 (en) 2002-02-20 2006-02-01 Sirna Therapeutics Inc RNA inhibition mediated inhibition of MAP KINASE GENES
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
MXPA04011624A (es) 2002-05-24 2005-03-07 Schering Corp Anticuerpo neutralizante humano anti-igfr.
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
KR20050109489A (ko) 2003-02-13 2005-11-21 화이자 프로덕츠 인크. 항-인슐린양 성장인자 ｉ 수용체 항체의 용도
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
BRPI0408317A (pt) 2003-03-14 2006-03-07 Pharmacia Corp anticorpos do receptor de igf-i para o tratamento de cáncer
CA2519113C (en) 2003-04-02 2012-06-05 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
EP2365001A3 (en) 2003-05-01 2012-03-28 Imclone LLC Fully human antibodies directed against the human insulin-like growth factor-1 receptor
US20050095611A1 (en) * 2003-05-02 2005-05-05 Chan Daniel W. Identification of biomarkers for detecting pancreatic cancer
AR046071A1 (es) 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
CN1835975B (zh) 2003-08-13 2012-11-21 辉瑞产品公司 经修饰的人类igf-1r抗体
ES2372694T3 (es) 2003-10-15 2012-01-25 OSI Pharmaceuticals, LLC Inhibidores de tirosina cinasa de imidazo[1,5-a]pirazina.
AR046639A1 (es) 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
WO2005053512A2 (en) * 2003-11-26 2005-06-16 Dana-Farber Cancer Institute, Inc. Animal models of pancreatic adenocarcinoma and uses therefor
WO2005058967A2 (en) 2003-12-16 2005-06-30 Pierre Fabre Medicament Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof
WO2005082415A2 (en) 2004-02-25 2005-09-09 Dana Farber Cancer Institute, Inc. Inhibitors of insulin-like growth factor receptor-1 for inhibiting tumor cell growth
EA200601687A1 (ru) 2004-03-12 2007-04-27 Аналитикон С.А. Тетрагидроизохинолиновые и тетрагидробензазепиновые производные (варианты), фармацевтическая композиция и фармацевтический набор, лекарственное и эталонное средство для тест-систем на их основе, способ лечения и профилактики заболевания, при котором благоприятна понижающая регуляция или ингибирование экспрессии или функции рецептора igf-1
MXPA06011423A (es) 2004-04-02 2007-01-23 Osi Pharm Inc Inhibidores de proteina cinasa heterobiciclica sustituida en el anillo 6,6-biciclico.
EP1796711A2 (en) 2004-04-22 2007-06-20 Oregon Health and Science University Herstatin or intron 8-encoded domain thereof for modulating signaling mediated by igf-1 receptor and erbb receptors
WO2006009962A2 (en) 2004-06-21 2006-01-26 Exelixis, Inc. Acacs as modifiers of the igf pathway and methods of use
MY139689A (en) 2004-07-20 2009-10-30 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
FR2873699B1 (fr) 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
MX2007001399A (es) 2004-08-02 2007-04-18 Osi Pharm Inc Compuestos que inhiben pirrolopirimidina multi-cinasa aril-amino sustituidas.
GB0426154D0 (en) 2004-11-29 2004-12-29 European Molecular Biology Lab Embl IGF-1 novel peptides
EP2281841A3 (en) 2004-12-03 2013-10-23 Merck Sharp & Dohme Corp. Biomarkers for pre-selection of patients for anti-IGF1R therapy
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
US8211929B2 (en) 2004-12-30 2012-07-03 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
AU2006264567A1 (en) 2005-05-05 2007-01-11 Valorisation Hsj, Societe En Commandite Cytokine receptor modulators and uses thereof
CA2678008C (en) 2005-06-17 2013-07-30 Imclone Systems Incorporated Methods of treating a secondary bone tumor with anti-pdgfralpha antibodies
WO2007000328A1 (en) 2005-06-27 2007-01-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Antibodies that bind to an epitope on insulin-like growth factor 1 receptor and uses thereof
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
WO2007029107A1 (en) 2005-09-09 2007-03-15 Analytecon Sa Isoquinolines derivatives as igf-1r inhibitors
EP1931636B1 (en) 2005-09-09 2011-04-13 Analytecon S.A. Isoquinolines as igf-1r inhibitors
US20090306116A1 (en) 2005-09-16 2009-12-10 Astrazeneca Ab Pyrimidine derivatives for the inhibition of igf-ir tyrosine kinase activity
AU2006292278B2 (en) 2005-09-20 2012-03-08 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
PL1979001T3 (pl) * 2005-12-13 2012-09-28 Medimmune Ltd Białka wiążące specyficzne dla insulinopodobnych czynników wzrostu i ich zastosowania
WO2007095113A2 (en) 2006-02-10 2007-08-23 Massachusetts Institute Of Technology Cpg15 and cpg15-2 compounds and inhibitors as insulin receptor and insulin-like growth factor receptor agonists and antagonists
EP1999131B1 (en) 2006-03-03 2013-10-23 Nerviano Medical Sciences S.r.l. Bicyclo-pyrazoles active as kinase inhibitors
WO2007099166A1 (en) 2006-03-03 2007-09-07 Nerviano Medical Sciences S.R.L. Pyrazolo-pyridine derivatives active as kinase inhibitors
JP2009532027A (ja) 2006-03-28 2009-09-10 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗ｉｇｆ−１ｒ抗体およびその使用
WO2008005469A2 (en) 2006-06-30 2008-01-10 Schering Corporation Igfbp2 biomarker
DE102006056784A1 (de) * 2006-12-01 2008-06-05 Meyer, Helmut E., Prof.Dr. Biomarker für die Diagnose von Pankreaskrebs
JP5666136B2 (ja) * 2007-02-01 2015-02-12 ジャンセン ダイアグノスティックス，エルエルシー 原発不明がんの原発巣を同定するための方法および材料
WO2008115470A2 (en) 2007-03-16 2008-09-25 East Carolina University Hox-gene expression as a biomarker for igf-1r therapeutics
EP2145021A2 (en) 2007-05-17 2010-01-20 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
US20110052667A1 (en) 2007-06-28 2011-03-03 Sylgen Laboratories, Inc. Compositions and methods for inhibiting angiogenesis and tumorigenesis
AU2008307634A1 (en) 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US8048621B2 (en) 2007-10-03 2011-11-01 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2195654A1 (en) * 2007-10-05 2010-06-16 National Institute for Bioprocessing Research and Training Limited Glycosylation markers for pancreatitis, sepsis and pancreatic cancer
EP2247757A2 (en) 2007-12-18 2010-11-10 Schering Corporation Biomarkers for sensitivity to anti-igf1r therapy
WO2009105154A2 (en) * 2008-02-19 2009-08-27 The Jackson Laboratory Diagnostic and prognostic methods for cancer
GB0803477D0 (en) 2008-02-26 2008-04-02 Ge Healthcare As Therapy selection method
US20090258365A1 (en) 2008-03-25 2009-10-15 Terstappen Leon W M M METHOD FOR DETECTING IGF1R/Chr 15 in CIRCULATING TUMOR CELLS USING FISH
US8198255B2 (en) * 2008-05-16 2012-06-12 The Board Of Regents Of The University Of Oklahoma SiRNA-mediated inhibition of doublecortin and Ca2+/calmodulin-dependent kinase-like-1
US20100081666A1 (en) * 2008-07-14 2010-04-01 Wyeth Src activation for determining cancer prognosis and as a target for cancer therapy
JP2012500631A (ja) 2008-08-20 2012-01-12 ザ リージェンツ オブ ザ ユニバーシティー オブ コロラド， ア ボディー コーポレイト Ｉｇｆ−１ｒ処置に対する癌の感受性を評価するためのマーカー
JP2012506238A (ja) 2008-10-20 2012-03-15 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト インスリン様増殖因子−１受容体キナーゼ阻害剤に対する抗がん反応を予測する生物学的マーカー
WO2010065765A2 (en) * 2008-12-04 2010-06-10 Aethlon Medical, Inc. Affinity capture of circulating biomarkers
US20110306514A1 (en) * 2009-01-14 2011-12-15 United States Department of Health and Human Services Ratio based biomarkers and methods of use thereof
EP2241634A1 (en) 2009-04-16 2010-10-20 Université Libre de Bruxelles Diagnostic method and tools to predict the effiacy of targeted agents against IGF-1 pathway activation in cancer
WO2010138908A1 (en) 2009-05-29 2010-12-02 Ventana Medical Systems, Inc. Igfir gene copy number as a prognostic marker in a non-small cell lung cancer
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
US10132811B2 (en) * 2009-06-25 2018-11-20 The Regents Of The University Of California Salivary transcriptomic and microbial biomarkers for pancreatic cancer
EP2475789A4 (en) 2009-09-09 2013-12-18 Quintiles Transnat Corp METHOD FOR PREDICTING THE RESPONSIBILITY OF A DISEASE OR A SLEEPING TO A RECEPTOR SYRINOIN INHIBITORY BY ANALYSIS OF MUTATIONS IN PIK3CA
US20110123441A1 (en) * 2009-10-23 2011-05-26 University Of Miami Novel greb1a monoclonal antibody
US20120220594A1 (en) 2009-10-30 2012-08-30 Bristol-Meyers Squibb Company Methods for treating cancer in patients having igf-1r inhibitor resistance
EP2507392A4 (en) 2009-11-30 2013-06-05 Merck Sharp & Dohme METHOD OF IDENTIFYING AND TREATING PATIENTS SENSITIVE TO ANTI-IGF-1R INHIBITION THERAPY
DK2517011T3 (en) 2009-12-22 2015-11-23 Expression Pathology Inc SRM / MRM analysis for the receptor protein for the insulin-like growth factor 1 (IGF-1R)
WO2011083391A2 (en) 2010-01-05 2011-07-14 Pfizer Inc. Biomarkers for anti-igf-ir cancer therapy
AU2011223655A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
AU2011223643A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011133668A2 (en) 2010-04-20 2011-10-27 President And Fellows Of Harvard College Methods and compositions for the treatment of cancer
DE102010026052A1 (de) 2010-06-30 2012-01-05 Siemens Aktiengesellschaft 11C-markiertes Peptid zur Detektion eines krankhaften Gewebes, das einen IGF-Rezeptor exprimiert
PT2829881T (pt) 2010-07-14 2017-11-29 Commw Scient Ind Res Org Diagnóstico para cancro colo-rectal

Similar Documents

Publication Publication Date Title
Guiu et al. Invasive lobular breast cancer and its variants: how special are they for systemic therapy decisions?
Goffin et al. Epidermal growth factor receptor: pathway, therapies, and pipeline
Morris et al. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer
Gautschi et al. A patient with lung adenocarcinoma and RET fusion treated with vandetanib
Sissung et al. Genetic variation: effect on prostate cancer
EP2524232A4 (en) METHOD FOR THE PROGNOSIS OF THE CONTACT OF TRIPLE-NEGATIVE BREAST CANCER ON A THERAPY
WO2011039734A3 (en) Use of genes involved in anchorage independence for the optimization of diagnosis and treatment of human cancer
HRP20241426T1 (hr) Derivati 5-(2-(2,5-difluorofenil)pirolidin-1-il)-3-(1h-pirazol-1-il)pirazolo[1,5-a]pirimidina i srodni spojevi kao inhibitori trk kinaze za liječenje raka
Alexandrowicz et al. Molluscs and ostracods of the Pleistocene loess deposits in the Halych site (Western Ukraine) and their significance for palaeoenvironmental reconstructions
JP2015524414A5 (enExample)
PL2720043T3 (pl) Przeciwciała HMGB1 i anty-HMGB1 do prognozowania zaburzeń neurologicznych
Demierre et al. A dramatic lung cancer course in a patient with a rare EGFR germline mutation exon 21 V843I: Is EGFR TKI resistance predictable?
EP2685989A4 (en) COMBINATION OF AN ANTI-CLUSTERIN OLIGONUCLEOTIDE AND AN ANDROGEN RECEPTOR ANTAGONIST FOR THE TREATMENT OF PROSTATE CANCER
Le Rhun et al. Patterns of response to crizotinib in recurrent glioblastoma according to ALK and MET molecular profile in two patients
Gründahl et al. Cutaneous angiosarcoma of head and neck: a new predictive score for locoregional metastasis
WO2013009809A3 (en) A method of determining the prognosis of hepatocellular carcinomas using a multigene signature associated with metastasis
PL2444811T3 (pl) Sposoby diagnozowania lub prognozowania raka jelita grubego
Bombonati et al. Metastases to and from the breast
Akhmadishina et al. DNA repair XRCC1, XPD genes polymorphism as associated with the development of bladder cancer and renal cell carcinoma
Mai et al. Invasive urothelial carcinoma exhibiting basal cell immunohistochemical markers: A variant of urothelial carcinoma associated with aggressive features
Jivapaisarnpong et al. Clinicopathological characteristics of mucinous and non-mucinous adenocarcinoma in the colon and rectum in Rajavithi Hospital, Thailand
Kim et al. Metastasis associated in colon cancer 1 predicts poor outcomes in patients with breast cancer
Tracy et al. The role of VEGF in growth of brain metastases from single cells as visualized by contrast enhanced MRI
Saif Small cell carcinoma of the colon arising in a carcinoid tumor
Hingorani Metastatic renal cell cancer progression with development of multiple brain metastasis: case report